HLA and malignancy : proceedings of a symposium presented by Roswell Park Memorial Institute, Buffalo, New York, August 19-20, 1976 / editor in chief: Gerald P. Murphy; associate editors: Elias Cohen, John E. Fitzpatrick, David Pressman.

Date:
1977
Catalogue details

Licence: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Credit: HLA and malignancy : proceedings of a symposium presented by Roswell Park Memorial Institute, Buffalo, New York, August 19-20, 1976 / editor in chief: Gerald P. Murphy; associate editors: Elias Cohen, John E. Fitzpatrick, David Pressman. Source: Wellcome Collection.

    265/270 (page 247)
    Index Ankylosing spondylitis, 2 B27 gene, 42-44, 48, 212 Anti-globulin cytotoxicity test (ACT), 3 Back pain, 44—45 j32-microglobulin, 189—97, 199 — 202 Bf factor, 12 — 15 Breast cancer HLA typing, 149—62, 163 — 66, 209-10 C2 deficiency, 11 — 15, 40—42 C4 deficiency, 14 C6 deficiency, 14—15, 40—42 Cancer HLA typing, 6, 181—85, 210—14 Cancer family syndrome, 159 — 62, 169-73 Chido antigen, 11 Diabetes, juvenile, 86 Gastric cancer, 29—36 Glyoxylase (GLO), 11 H-2 region, 2, 6, 9, 214 Half-deficits in components of complement, 39 HLA-A locus, 1,4, 6, 9-10, 15-16, 30-36 breast cancer, 149—62, 163—66 cancer, 131—42, 145—47 Hodgkin's disease, 205 — 14, 217-26 leukemia, 64-67, 73-77, 81-86, 103-6, 1 15-27, 131-32 malignant melanoma, 175—79 retinoblastoma, 231—37 HLA-B locus, 1,2, 6, 9-16, 30-36 breast cancer, 163—66 cancer, 131 —42 Hodgkin's disease, 131, 205 — 14, 217-26 leukemia, 73—77, 81—88, 103—6, 115-27 malignant melanoma, 175—79 retinoblastoma, 231—37 HLA-C locus, 1, 9, 11-12 cancer, 214 malignant melanoma, 175—79 HLA-D locus, 1-2, 10-14 cancer, 137, 142, 214, 217-19, 223-26 malignant melanoma, 175—79 retinoblastoma, 231, 236 Hodgkin's disease, 7, 21 HLA-B locus, 131, 134, 205-14 HLA typing, 205-14, 217-26 Immune responsiveness, 39, 45—49, 77-78, 141 malignant melanoma, 175—79, 214 Leukemia, acute, 2, 6, 65-67, 71—78, 81-88, 91-100, 103-6, 131 cytotoxicity, 109-13 HLA typing, 91-100, 1 15-27, 132 Leukemia associated antigen(s), 65, 81, 91, 109, 131 Linkage disequilibrium, 132, 137, 142,214 Lymphocyte-activating determinant (LADi), 10 Lymphocyte-dependent-antibody- mediated reactions (LDA), 3, 4-6 Lymphoreticular cells, 91 -100 247